XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Cash flows from operating activities:    
Loss for the period $ (5,383,155) $ (7,672,266)
Adjustments to reconcile (loss) for the period to net cash used in operating activities:    
Depreciation 58,789 50,341
Stock-based compensation 1,577,016 2,072,030
Change in the fair value of warrants with down-round protection (251,790) (273,733)
Linkage difference on principal of loans from stockholders (1,266) 373
Changes in assets and liabilities:    
Decrease in accounts receivable (5,590) (18,748)
Increase in inventory 20,979 49,255
(Decrease) increase in other current assets (31,717) 256,997
(Decrease) increase in accounts payable (165,580) 235,138
Increase in other current liabilities 379,854 203,752
Decrease in liability for employee rights upon retirement   (10,148)
Net cash used in operating activities (3,802,460) (5,107,009)
Cash flows from investing activities:    
Purchase of property and equipment (3,505) (19,467)
Increase in long-term restricted cash (10,164)  
Net cash used in investing activities (13,669) (19,467)
Cash flows from financing activities    
Cash dividend on Series A Preferred Stock (5,143)
Proceeds allocated to Series C Preferred Stock, net of cash issuance expenses 3,598,254
Proceeds allocated to Series C Warrants, net of cash issuance expenses 1,780,963
Proceeds allocated to Common Stock from Series D offering, net of cash issuance expenses 2,563,839
Proceeds allocated to Series D Warrants, net of cash issuance expenses 2,141,989
Net cash provided by (used in) financing activities 4,705,828 5,374,074
Effect of exchange rate changes on cash and cash equivalents (1,612) 65,274
Increase in cash and cash equivalents 888,087 312,872
Cash and cash equivalents at beginning of the period 53,782 148,836
Cash and cash equivalents at end of the period $ 941,869 $ 461,708